|
gptkbp:instance_of
|
gptkb:immunotherapy
|
|
gptkbp:administered_by
|
oral tablet
inhalation solution
|
|
gptkbp:approves
|
gptkb:1971
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Copegus
gptkb:Rebetol
|
|
gptkbp:can_be_combined_with
|
gptkb:Interpol
gptkb:peginterferon
|
|
gptkbp:casnumber
|
36791-04-5
|
|
gptkbp:chemical_formula
|
C8 H11 N5 O5 P
|
|
gptkbp:class
|
nucleoside analog
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
|
|
gptkbp:clinical_use
|
combination therapy
monotherapy
|
|
gptkbp:composed_by
|
phosphorylation
chemical modification
nucleoside analog synthesis
|
|
gptkbp:contraindication
|
pregnancy
severe renal impairment
|
|
gptkbp:developed_by
|
gptkb:Merck_&_Co.
|
|
gptkbp:discovery
|
gptkb:United_States
|
|
gptkbp:discovery_year
|
1970s
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ribavirin
|
|
gptkbp:interacts_with
|
gptkb:didanosine
gptkb:zidovudine
gptkb:azathioprine
|
|
gptkbp:invention
|
patented
generic available
|
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Australia
gptkb:Canada
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
inhibits viral RNA synthesis
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
half-life 12-40 hours
oral bioavailability 45% to 65%
|
|
gptkbp:research_areas
|
viral infections
chronic hepatitis C
RSV in infants
|
|
gptkbp:side_effect
|
gptkb:anemia
gptkb:depression
fatigue
headache
nausea
rash
insomnia
thrombocytopenia
hypersensitivity reaction
|
|
gptkbp:target_virus
|
gptkb:Venezuelan_equine_encephalitis_virus
gptkb:HCV
RSV
|
|
gptkbp:used_for
|
treating hepatitis C
treating respiratory syncytial virus (RSV) infection
|
|
gptkbp:bfsParent
|
gptkb:Sovaldi
gptkb:AZT
gptkb:ledipasvir
|
|
gptkbp:bfsLayer
|
5
|